A 52 kd cellular protein, FK506-binding protein (FKBP52), phosphorylated at tyrosine residues by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), inhibits adeno-associated virus 2 (AAV2) second-strand DNA synthesis and transgene expression. FKBP52 is dephosphorylated at tyrosine residues by T-cell protein tyrosine phosphatase (TC-PTP), and TC-PTP over-expression leads to improved viral second-strand DNA synthesis and improved transgene expression. In these studies, we observed that perturbation of EGFR-PTK signaling by a specific inhibitor, Tyrphostin 23 (Tyr23), augmented the transduction efficiency of the single-stranded AAV (ssAAV) vector as well as the self-complementary AAV (scAAV) vector. Similarly, tyrosine-dephosphorylation of FKBP52 by TC-PTP resulted in increased transduction by both vectors. These data suggested that EGFR-PTK signaling also affects aspects of AAV transduction other than viral second-strand DNA synthesis. We document that inhibition of EGFR-PTK signaling leads to decreased ubiquitination of AAV2 capsids which, in turn, facilitates nuclear transport by limiting proteasomemediated degradation of AAV vectors. We also document that Tyr23-mediated increase in AAV2 transduction efficiency is not further enhanced by a specific proteasome inhibitor, MG132. Thus, EGFR-PTK signaling modulates ubiquitin (Ub)/proteasome pathway-mediated intracellular trafficking as well as FKBP52-mediated second-strand DNA synthesis of AAV2 vectors. This has implications in the optimal use of AAV vectors in gene therapy.
A 52 kd cellular protein, FK506-binding protein (FKBP52), phosphorylated at tyrosine residues by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), inhibits adeno-associated virus 2 (AAV2) second-strand DNA synthesis and transgene expression. FKBP52 is dephosphorylated at tyrosine residues by T-cell protein tyrosine phosphatase (TC-PTP), and TC-PTP over-expression leads to improved viral second-strand DNA synthesis and improved transgene expression. In these studies, we observed that perturbation of EGFR-PTK signaling by a specific inhibitor, Tyrphostin 23 (Tyr23), augmented the transduction efficiency of the single-stranded AAV (ssAAV) vector as well as the self-complementary AAV (scAAV) vector. Similarly, tyrosine-dephosphorylation of FKBP52 by TC-PTP resulted in increased transduction by both vectors. These data suggested that EGFR-PTK signaling also affects aspects of AAV transduction other than viral second-strand DNA synthesis. We document that inhibition of EGFR-PTK signaling leads to decreased ubiquitination of AAV2 capsids which, in turn, facilitates nuclear transport by limiting proteasomemediated degradation of AAV vectors. We also document that Tyr23-mediated increase in AAV2 transduction efficiency is not further enhanced by a specific proteasome inhibitor, MG132. Thus, EGFR-PTK signaling modulates ubiquitin (Ub)/proteasome pathway-mediated intracellular trafficking as well as FKBP52-mediated second-strand DNA synthesis of AAV2 vectors. This has implications in the optimal use of AAV vectors in gene therapy.
INTRODUCTION
The adeno-associated virus 2 (AAV2), a non-pathogenic human parvovirus, has gained attention as an alternative to the more commonly used retrovirus-and adenovirus-based vectors in gene transfer and gene therapy. 1, 2 Recombinant AAV2 vectors are currently in use in Phase I/II clinical trials for gene therapy in a number of diseases such as cystic fibrosis, α-1 anti-trypsin deficiency, Parkinson's disease, Batten's disease, and muscular dystrophy, [3] [4] [5] and have been shown to transduce a wide variety of cells and tissues in vitro and in vivo. 2, [6] [7] [8] We and others have undertaken systematic studies to elucidate some of the fundamental steps in the life cycle of AAV vectors, including viral binding, entry, [9] [10] [11] [12] [13] intracellular trafficking, [14] [15] [16] [17] uncoating, 18, 19 second-strand DNA synthesis [20] [21] [22] [23] [24] [25] [26] [27] [28] and viral genome integration into host cell chromosome. 29, 30 Two independent laboratories have described that the viral second-strand DNA synthesis is a rate-limiting step, which accounts for inefficient transduction of certain cell types by AAV vectors. 20 , 21 We have reported that a cellular protein, designated FKBP52, which interacts with the single-stranded D-sequence in the AAV2 inverted terminal repeat, is phosphorylated at tyrosine residues by the epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK), and inhibits the viral second-strand DNA synthesis, thereby leading to inefficient transgene expression. 24 We have also documented that FKBP52 is dephosphorylated at tyrosine residues by T-cell protein tyrosine phosphatase (TC-PTP), and this negatively regulates EGFR-PTK signaling, leading to efficient viral second-strand DNA synthesis. 25 Tyrosinedephosphorylation of FKBP52 in TC-PTP-transgenic mice, and removal of FKBP52 in FKBP52 knockout mice also leads to efficient AAV2 transduction of murine hepatocytes in vivo.
www.moleculartherapy.org vol. 15 no. 7 july 2007 © The American Society of Gene Therapy fibroblast, 14, 15 we documented that AAV2 vectors failed to traffic to the nucleus efficiently, but over-expression of TC-PTP in TC-PTP-transgenic mice facilitated this process. 19 These studies suggested that TC-PTP and/or EGFR-PTK signaling are involved in AAV2 intracellular trafficking.
In these studies, we have systematically examined the role of EGFR-PTK signaling in ubiquitination, intracellular trafficking, and AAV-mediated transgene expression. We document here that, in addition to augmenting viral second-strand DNA synthesis, perturbations in EGFR-PTK signaling affect AAV2 transduction efficiency by facilitating intracellular trafficking from cytoplasm to nucleus. Because receptor endocytosis is affected by the free Ub content within a cell, that regulates lysosomal degradation of EGFR with proteasome inhibitors, 33 and also because proteasome inhibitors augment AAV transduction, 16, [31] [32] [33] [34] [35] and protein phosphorylation modulates ubiquitination of cellular and viral proteins, [36] [37] [38] [39] [40] [41] [42] we hypothesized that inhibition of EGFR-PTK signaling decreases ubiquitination of AAV2 capsid proteins. This suggests that ubiquitination followed by proteasome-mediated degradation of AAV2 capsid proteins is also affected by EGFR-PTK. These studies suggest that complex interactions between EGFR-PTK signaling and the Ub/proteasome pathway play a role in AAV-mediated transduction. This is likely to be important in yielding new insights in the optimal use of recombinant AAV vectors in human gene therapy.
RESULTS

Inhibition of EGFR-PTK signaling increases transduction by both ssAAV2 and scAAV2 vectors
In our previously published studies, [23] [24] [25] 27, 43 we documented that the inhibition of EGFR-PTK signaling leads to dephosphorylation of FKBP52 at tyrosine residues, and facilitates viral second-strand DNA synthesis, thereby resulting in efficient transgene expression. Since double-stranded self-complementary AAV2 (scAAV2) vectors, 44, 45 which bypass the requirement for second-strand DNA synthesis, achieve much higher transduction efficiency, we set out to address the following prediction: scAAV2-mediated transgene expression should not be influenced by the inhibition of EGFR-PTK signaling if viral second-strand DNA synthesis is the sole mechanism involved. In the first set of experiments, HeLa cells were treated with Tyrphostin 23 (Tyr23), which is a specific inhibitor of EGFR-PTK, 43 and then transduced with recombinant single-stranded AAV2 enhanced green fluorescence protein (ssAAV2-EGFP) or scAAV2-EGFP vectors. Transgene expression was determined 48 hours post-transduction. From the results shown in Figure 1a , it is evident that whereas mock-infected HeLa cells showed no green fluorescence, only ~3% of HeLa cells transduced with the ssAAV2-EGFP vector were EGFP-positive, and Tyr23 treatment led to a ~12-fold increase in ssAAV transduction efficiency (Figure 1b) . These findings are consistent with our previously published reports. [23] [24] [25] 27, 43 As expected, the transduction efficiency of scAAV vectors was approximately fourfold higher compared with that of their single-stranded counterparts but, surprisingly, Tyr23 treatment also led to a further approximately tenfold increase in the transduction efficiency of scAAV vectors (Figure 1b) . This increase was not due to contamination of scAAV vectors with ssAAV vectors, the generation of which we have recently documented. 46 These data suggest that perturbations in EGFR signaling affect additional aspects of AAV-mediated transduction beyond viral second-strand DNA synthesis.
Because stable transfection with a TC-PTP expression plasmid leads to inhibition of EGFR-PTK signaling and efficient transgene expression mediated by ssAAV vectors, 25 we reasoned that deliberate over-expression of TC-PTP would also lead to a significant increase in transduction efficiency of scAAV2 vectors. HeLa cells were either mock-transfected or stably transfected with the wildtype (wt)-or a C-S mutant (m)-TC-PTP expression plasmid, and were infected with ssAAV2-EGFP or scAAV2-EGFP vectors. Transgene expression was visualized 48 hours post-infection. As can be seen in Figure 2a , whereas mock-infected HeLa cells showed no green fluorescence, and only ~3% of mock-transfected cells that had been transduced with the ssAAV-EGFP vector were EGFP-positive, a significant increase (~15-fold) was obtained in the transduction efficiency of ssAAV2 vectors in cells stably transfected with the wtTC-PTP expression plasmid. This, again, is consistent with our previously published reports. 22, 27 This increase was not observed when the mTC-PTP expression plasmid was used. It is noteworthy that although the transduction efficiency of scAAV2 vectors in HeLa cells is approximately eightfold higher compared with their ss counterparts, stable transfection with the wtTC-PTP expression plasmid leads to a further approximately tenfold increase (Figure 2b ). These data corroborate the proposition that inhibition of EGFR-PTK signaling by pre-treatment with Tyr23 or over-expression of TC-PTP augments AAV2 transduction, which involves other mechanism(s) in addition to facilitating viral second-strand DNA synthesis.
Nuclear transport of AAV is improved following perturbation of EGFR-PTK signaling, or proteasome inhibition
We have previously documented that over-expression of TC-PTP in TC-PTP-transgenic mice facilitated AAV2 vector transport to the nucleus in primary murine hematopoietic cells, 19 thereby suggesting that EGFR-PTK signaling might also be involved in AAV trafficking. To further examine this hypothesis, we examined the fate of the input viral DNA in cells treated with Tyr23, or stably transfected with the wtTC-PTP. Mock-treated cells, cells stably transfected with mTC-PTP, and cells treated with MG132, a specific inhibitor of proteasome 16, 31, 32 known to augment AAV nuclear transport, 16, 34, 35 were used as appropriate controls. Nuclear and cytoplasmic fractions were obtained 12 hours post-infection, and low M r DNA was isolated from these fractions and electrophoresed on 1% agarose gels. This was followed by Southern blot analysis ( Figure 3a ) and densitometric scanning of autoradiographs ( Figure 3b) . As is evident, ~64% of the input ssAAV DNA was present in the cytoplasmic fraction in control cells (lane 1). Consistent with previously published studies, 16, 34, 35 pre-treatment with MG132 improved AAV2 trafficking to the nucleus up to ~62% (lane 10). Interestingly, in cells pre-treated with Tyr23, or stably transfected with the wtTC-PTP, the input ssAAV2 DNA in the nuclear fraction was as high as ~52 and ~54%, respectively (lanes 4 and 8). In cells transfected with the mTC-PTP, on the other hand, only ~38% of the input ssAAV DNA was present in the nuclear fraction (lane 6), which was similar to that in control cells (lane 2). We considered the possibility that Tyr23 and TC-PTP could affect transcriptional and translational events to increase transgene expression, since they do not enhance nuclear delivery of AAV as well as MG132 does. This was ruled out because, in plasmid DNA-mediated transfection of HeLa cells, neither treatment with Tyr23, nor over-expression of TC-PTP resulted in any increase in transgene expression (Supplementary Figure S1 ). These results further support the proposition that inhibition of EGFR-PTK signaling facilitates nuclear transport of AAV vectors. 
Transduction efficiency of both ssAAV and scAAV vectors in cells with perturbed EGFR-PTK signaling is not further enhanced by proteasome inhibition
We next examined whether inhibition of EGFR-PTK signaling by treatment with Tyr23 or over-expression of TC-PTP modulates the Ub/proteasome pathway involved in AAV2 transduction. We did this because the free Ub content within a cell (that regulates lysosomal degradation of EGFR), and proteasome inhibitors have been implicated in the regulation of EGFR endocytosis, 33 proteasome inhibitors have been shown to augment AAV transduction, 16, 31, 32, 34, 35 and protein phosphorylation has been implicated in the regulation of ubiquitination of cellular and viral proteins. [36] [37] [38] [39] [40] [41] [42] Cells were mock-treated or treated with Tyr23, MG132, or both; and cells stably transfected with either wt-or mTC-PTP expression plasmids were either mock-treated or treated with MG132. All treated cells and appropriate controls were infected with recombinant ssAAV2-lacZ or scAAV2-EGFP vectors, and transgene expression was determined 48 hours post-transduction. The results are shown in Figure 4a . Consistent with previously published studies, [23] [24] [25] 27, 43 >5% of cells that were transduced with ssAAV2 vectors were lacZ-positive, whereas in cells overexpressing wtTC-PTP, and in those pre-treated with Tyr23, there was ~13-fold and ~20-fold increase, respectively, in transduction efficiency of ssAAV vectors (Figure 4b) . Treatment with MG132 for 4 hours (2 hours for pretreatment and 2 hours for treatment), together with AAV2 infection, led to an approximately sixfold increase in transduction efficiency of ssAAV2 vectors (Figure 4b) . Surprisingly, however, the transduction efficiency of ssAAV2 vectors following pre-treatment with Tyr23, or TC-PTP over-expression, was not further enhanced by MG132. Similar results were obtained when scAAV-EGFP vectors were used under identical conditions. As can be seen in Figure 5a , whereas mock-infected cells showed no green fluorescence, and ~15% of mock-treated cells transduced with scAAV2 vectors were EGFP-positive, overexpression of TC-PTP, or pre-treatment with Tyr23 led to approximately fivefold and approximately ninefold increases, respectively, in the transduction efficiency of scAAV2 vectors (Figure 5b) . Treatment with MG132 led to an approximately fivefold increase in scAAV2 transduction efficiency (Figure 5b ). This increase was not observed when the mTC-PTP expression plasmid was used. It is noteworthy that the transduction efficiency of scAAV2 vectors following pre-treatment with Tyr23 or over-expression of TC-PTP, was not further enhanced by MG132 (Figure 5b) . Similar results were obtained when lower viral particles/cell (1,000 and 2,000) ratios were used (Supplementary Figure S2) . These data further suggest that inhibition of EGFR-PTK signaling modulates the Ub/proteasome pathway, and this affects aspects of intracellular trafficking as well as second-strand DNA synthesis of AAV2 vectors.
Inhibition of EGFR-PTK signaling decreases ubiquitination of AAV2 capsid proteins
The Ub-proteasome pathway plays an important role in the cell by specifically degrading both endogenous and foreign proteins. 47 A previous study 48 reported that immunoprecipitated AAV2 capsid proteins from infected cell lysates are conjugated with Ub and heat-denatured virus particles are substrates for in vitro ubiquitination. A more recently study 42 documented that casein kinase II-induced phosphorylation of serine residue 301 promotes ubiquitination and degradation of the bovine papillomavirus E2 protein by the proteasome pathway. In order to examine further whether EGFR-signaling is involved in ubiquitination of AAV2 capsid proteins, two sets of experiments were carried out. In the first set, cells were either mock-treated or treated with MG132, Tyr23, or both; and cells stably transfected with either the wtor mTC-PTP expression plasmids were either mock-treated or treated with MG132 as described in Materials and Methods. Whole cell lysates (WCLs) were prepared and equivalent amounts of proteins were subjected to western blot analyses with anti-Ub monoclonal antibody. The results are shown in Figure 6 . The total level of smeary ubiquitinated cellular proteins was low in untreated cells (lanes 1 and 6) , and remained unchanged in Tyr23-teated cells (lane 3) as well as in cells stably transfected with either wt-or mTC-PTP expression plasmids (lanes 4 and 5). However, because these molecules are quickly degraded by the proteasome after ubiquitination, a significant accumulation of smeary ubiquitinated proteins in HeLa cells, following the inhibition of proteasome activity by treatment with MG132, was observed as expected (lanes 2 and 7) . Interestingly, however, both Tyr23 treatment and over-expression of wtTC-PTP significantly decreased the accumulation of MG132-induced ubiquitinated proteins (lanes 8 and 10), whereas over-expression of mTC-PTP had no effect (lane 9). In the second set of experiments, all mock-treated and treated cells were infected with AAV2 for 2 hours at 37 °C. WCL were prepared at 4 hours post-infection and equivalent amounts of proteins were immunoprecipitated with anti-AAV2 capsid antibody A20. This was followed by Western blot analyses with anti-Ub monoclonal antibody. Similar results, shown in Figure 7 , indicate that whereas the ubiquitinated AAV2 capsid proteins (Ub-AAV2 Cap, bracket) were undetectable in mock-infected cells (lanes 1 and 2) , and the signal of ubiquitinated AAV2 capsid proteins was weaker in untreated cells (lane 3) and unchanged in Tyr23-treated cells (lane 4) as well as in cells stably transfected with wtTC-PTP expression plasmid (lane 7), a significant accumulation of ubiquitinated AAV2 capsid proteins occurred following treatment with MG132 (lane 5). However, treatment with Tyr23, or over-expression of wtTC-PTP dramatically inhibited the extent of accumulation of MG132-induced ubiquitinated AAV2 capsid proteins (lanes 6 and 8). These results indicate that inhibition of EGFR protein tyrosine kinase signaling also decreases the ubiquitination of total cellular proteins and of AAV2 capsid proteins.
DISCUSSION
Systematic studies have been undertaken by a number of investigators in the recent past to elucidate some of the fundamental steps in the life cycle of AAV. In our previous studies, 19 we documented that intracellular trafficking of AAV2 from cytoplasm to nucleus is improved in murine hematopoietic stem cells from TC-PTP-transgenic mice. These data suggested that, in addition to its crucial role in viral second-strand DNA synthesis, EGFR-PTK signaling may also be involved in intracellular trafficking and/or nuclear transport of AAV2. The Ub-proteasome pathway plays an essential role in AAV2 intracellular trafficking, and proteasome inhibitors can promote AAV2 nuclear transport, leading to augmentation of AAV2 transduction. 16, 31, 32 Direct evidence has been presented for ubiquitination of AAV2 capsid proteins in HeLa cells and in in vitro ubiquitination assays. 48 Only denatured AAV2 capsids could be ubiquitinated in vitro and not intact AAV2, thereby indicating that the intact AAV2 capsid requires a conformational change, or a modification such as phosphorylation before its ubiquitination. A number of studies have reported that phosphorylation of cellular proteins by tyrosine or serine/threonine protein kinase is required for efficient ubiquitination and degradation of these proteins. [36] [37] [38] [39] [40] [41] [42] For example, phosphorylation of inhibitory κBα (IκBα) at serines 32 and 36 is a pre-requisite for cytokine-induced IκBα ubiquitination and degradation. 36, 37 Receptor-mediated tyrosine kinase activation has been shown to be a requirement for T-cell antigen receptor ubiquitination, 38 and ubiquitination of CD16 ζ chain in human NK cells following receptor engagement has been shown to be tyrosine kinase-dependent. 39 Modification of bovine papillomavirus E2 transactivator protein by ubiquitination was reduced by mutation of serine 301, thereby indicating that phosphorylation of this residue is required for efficient ubiquitination and degradation of this protein by the Ub-proteasome pathway. 41 Furthermore, casein kinase II-induced phosphorylation of serine 301 of E2 protein induced a conformational change and decreased the local thermodynamic stability of this region, promoting ubiquitination and targeted degradation of the E2 protein by the proteasome pathway. 42 Further efforts to determine whether EGFR-PTK-induced tyrosine phosphorylation of AAV2 capsid proteins also promotes ubiquitination and degradation of AAV2, and whether such an interaction between EGFR-PTK signaling and the Ubproteasome pathway is involved in the regulation of aspects of intracellular trafficking of AAV2 vectors, have led to these studies in which we have documented that EGFR-PTK signaling is indeed involved in the Ub-proteasome pathway for modulation of nuclear transport of AAV2 vectors in addition to regulating viral second-strand DNA synthesis in HeLa cells. Similar results were obtained with the murine fibroblast cell line NIH3T3, adult mouse hepatocyte cell line H2.35, and fetal mouse hepatocyte cell line FL83B (data not shown). On the basis of all available data, we propose a model, shown schematically in Figure 8 , which helps explain the interactions between EGFR-PTK signaling and Ub/proteasome pathway in modulating intracellular trafficking of AAV2 vectors as well as viral second-strand DNA synthesis. In this model, following infection through binding to its primary cellular receptor heparan sulfate proteoglycan, and entry mediated by a co-receptor(s) such as FGFR1, AAV2 enters into the early endosome through clathrin-coated pits-mediated endocytosis. The early endosome then matures into late endosome, in which AAV is degraded by lysosomal enzymes if it fails to escape from the late endosome. If AAV2 escapes into the cytoplasm perinuclearly, it is ubiquitinated. We hypothesize that EGFR-PTK-mediated phosphorylation of capsid proteins at tyrosine residues is a pre-requisite for ubiquitination. A substantial number of ubiquitinated virions are then recognized and degraded by cytoplasmic proteasomes on their way to the nucleus, leading to inefficient nuclear transport (open arrow). In the presence of proteasome inhibitors, vector degradation is reduced, leading to more efficient nuclear transport of AAV. Inhibition of AAV2 capsid phosphorylation at tyrosine residues by EGFR-PTK inhibitors results in decreased ubiquitination of intact virions, which in turn escape proteasome-mediated degradation. This is an effect similar to what is seen with proteasome inhibitors. The net result is that intact virions enter the nucleus more efficiently (closed arrow). Following uncoating in the nucleus, the D-sequence in the AAV2 inverted terminal repeat forms a complex with FKBP52 [F], which is phosphorylated at tyrosine residues [P] by EGFR-PTK, inhibiting viral second-strand DNA synthesis. EGFR-PTK inhibitors prevent phosphorylation of FKBP52 at tyrosine residues, and dephosphorylated FKBP52 no longer binds to the AAV2 D-sequence, thereby facilitating viral second-strand DNA synthesis and leading to efficient transgene expression. Consistent with this model, we have observed that AAV2 capsids can indeed be phosphorylated at tyrosine residues by EGFR-PTK in in vitro phosphorylation assays, and that phosphorylated AAV2 virions transduce cells much less efficiently (L.Z., B.L., S.Z., L.G., M.A.-M., and A.S., unpublished data). Our currently ongoing studies on in vitro phosphorylation followed by ubiquitination of AAV2 capsid, and site-directed mutational analyses of surface-exposed tyrosine residues on AAV2 capsid proteins, should allow us to gain a better understanding of the role of AAV2 capsid phosphorylation and ubiquitination in various steps in the life cycle of AAV2. This may have implications in the optimal use of recombinant AAV2 vectors in gene therapy. Highly purified stocks of ss recombinant AAV2 vectors containing the β-galactosidase (lacZ) reporter gene, or red fluorescence protein gene, or ss and sc recombinant AAV2 vectors containing EGFP gene driven by the cytomegalovirus immediate-early promoter (ssAAV2-lacZ, ssAAV2-red fluorescence protein, ssAAV2-EGFP or scAAV2-EGFP) were generated as described previously. 49 Physical particle titers of recombinant vector stocks were determined by quantitative DNA slot blot analysis. Horseradish peroxidase-conjugated antibody specific for Ub (mouse monoclonal immunoglobulin G 1 (IgG 1 ), clone P4D1), and normal mouse IgG 1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies specific for intact AAV2 particles (mouse monoclonal IgG 1 , clone A20) were obtained from Research Diagnostics (Flanders, NJ). MG132 was purchased from Calbiochem (La Jolla, CA), and all other chemicals used were purchased from Sigma-Aldrich (St. Louis, MO).
MATERIALS AND METHODS
Cells
Recombinant AAV vector transduction assay. Approximately 1 × 10
5 HeLa cells were plated in each well in 12-well plates and incubated at 37 °C for 12 hours. Cells were washed once with Iscove's-modified Dulbecco's medium and then infected at 37 °C for 2 hours with 5 × 10 3 particles per cell of recombinant AAV2-lacZ, ssAAV2-EGFP or scAAV2-EGFP vectors as described previously. 24, 26, 28 Cells were incubated in complete Iscove'smodified Dulbecco's medium containing 10% newborn calf serum and 1% antibiotics for 48 hours. For lacZ expression, cells were fixed and stained with X-Gal (5-bromo-4-chloro-3-indolyl-d-galactopyranoside). The transduction efficiency was measured by GFP imaging using a LEICA DM IRB/E fluorescence microscope (Leica Microsystems, Wetzlar, Germany). Images from three visual fields of mock-infected and vectorinfected HeLa cells at 48 hours post-injection were analyzed quantitatively by ImageJ analysis software (National Institutes of Health, Bethesda, MD). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field (mean ± SD). Analysis of variance was used for comparing test results with the control, and the results were determined to be statistically significant.
Isolation of nuclear and cytoplasmic fractions from HeLa cells. Nuclear and cytoplasmic fractions were isolated from HeLa cells as described earlier. 19 In brief, cells mock-infected or infected with recombinant AAV2-lacZ vectors were washed twice with phosphate-buffered saline 12 hours post-infection. Cells were treated with 0.01% trypsin and washed extensively with phosphate-buffered saline to remove any adsorbed and unadsorbed virus particles. Cell pellets were gently resuspended in 200 µl hypotonic buffer (10 mmol/l HEPES, pH 7.9. 1.5 mmol/l MgCl 2 , 10 mmol/l KCl, 0.5 mmol/l dithiothreitol, 0.5 mmol/l phenylmethanesulfonylfluoride) and incubated on ice for 5 minutes, after which 10 µl 10% NP-40 was added to each tube for ~3 minutes, and observed under a light microscope. Samples were mixed gently and centrifuged for 5 minutes at 500 rpm at 4 °C. Supernatants (cytoplasmic fractions) were decanted and stored on ice. Pellets (nuclear fractions) were washed twice with 1 ml hypotonic buffer and stored on ice. The purity of each fraction was determined to be >95%, as measured by the absence of acid phosphatase activity (nuclear fractions) and absence of histone H3 (cytoplasmic fractions) as described previously. 14, 19 Southern blot analysis for AAV trafficking. Low M r DNA samples from nuclear and cytoplasmic fractions were isolated and electrophoresed on 1% agarose gels or 1% alkaline-agarose gels followed by Southern blot hybridization using a 32 P-labeled lacZ-specific DNA probe as described earlier. 14, 19 Densitometric scanning of autoradiographs for the quantitation was evaluated with ImageJ analysis software (National Institutes of Health, Bethesda, MD).
Preparation of WCL and co-immunoprecipitation. WCL were prepared as described earlier, 17, 26, 50 with the following modifications: 2 × 10 6 HeLa cells were either mock-treated, or treated with 500 mmol/l Tyrphostin 23, 4 mmol/l MG132, or both for 4 hours (treatment with MG132 for 2 hours and then with Tyr23 for an additional 2 hours). Cells were mock-infected or infected with ssAAV-red fluorescence protein vectors at 10 4 particles/ cell for 2 hours at 37 °C. Mock-transfected cells and cells stably transfected with wt-or mTC-PTP expression plasmids were treated with MG132 and also subjected to mock-infection or infection with ssAAV-red fluorescence protein vectors. For cellular protein analyses, treated or mocktreated cells were lysed on ice in cell lysis buffer (1% Triton X-100, 10% glycerol, 50 mmol/l HEPES, pH 7.5, 150 mmol/l NaCl, 1.5 mmol/l MgCl 2 , 1 mmol/l EDTA) containing 1 mmol/l dithiothreitol, 10 mmol/l NaF, 2 mmol/l Na 3 VO 4 , 0.5 mmol/l phenylmethanesulfonylfluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml pepstatin. For immunoprecipitation, cells were treated with 0.01% trypsin and washed extensively with phosphate-buffered saline to remove any adsorbed and unadsorbed virus particles after treatment or at 4 hours post-infection, and then resuspended in 2 ml hypotonic buffer (20 mmol/l HEPES pH 7.5, 5 mmol/l KCl, 0.5 mmol/l MgCl 2 ) containing 1 mmol/l dithiothreitol, 10 mmol/l NaF, 2 mmol/l Na 3 VO 4 , 0.5 mmol/l phenylmethanesulfonylfluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml. WCL were prepared by homogenization in a tight-fitting Duall tissue grinder until ~95% cell lysis was achieved as monitored by trypan blue dye exclusion assay. WCL were cleared of non-specific binding by incubation with 0.25 µg of normal mouse IgG together with 20 υl of protein G-agarose beads for 60 minutes at 4 °C in an orbital shaker. After preclearing, 2 µg of capsid antibody against intact AAV2 particles (A20) (mouse IgG 1 ) was added and incubated at 4 °C for 1 hour, followed by precipitation with protein G-agarose beads at 4 °C for 12 hours in a shaker. Pellets were collected by centrifugation at 2,500 rpm for 5 minute at 4 °C and washed four times with phosphate-buffered saline. After the final wash, supernatants were aspirated and discarded, and pellets were resuspended in equal volume of 2 × sodium dodecyl sulfate sample buffer. Twenty milliliters of resuspended pellet solutions were used for Western blotting with horseradish peroxidase-conjugated anti-Ub antibody as described below.
Western blot analyses.
Western blotting was performed as described previously 17, 26, 50 For cellular protein analyses, equivalent amounts (~5 µg) of WCL samples were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to Immobilon-P membranes (Millipore, Bedford, MA). For immunoprecipitation, resuspended pellet solutions were boiled for 2-3 minutes and 20 µl of samples were used for sodium dodecyl sulfate polyacrylamide gel electrophoresis. Membranes were blocked at 4 °C for 12 hours with 5% nonfat milk in 1 × Trisbuffered saline (20 mmol/l Tris-HCl, pH 7.5, 150 m NaCl). Membranes were treated with monoclonal horseradish peroxidase-conjugated antiUb antibody (1:2,000 dilution). Immunoreactive bands were visualized using chemiluminescence (ECL-plus, Amersham Pharmacia Biotech, Piscataway, NJ). 
